XML 27 R6.htm IDEA: XBRL DOCUMENT

Business Overview	3 Months Ended
Business Overview	Sep. 30, 2014
Accounting Policies [Abstract]
Business Overview	Business Overview Company Description Cardiovascular Systems, Inc. (the “Company”) develops, manufactures and markets devices for the treatment of vascular diseases. The Company’s peripheral arterial disease products, the Stealth 360°^® PAD System, Diamondback 360^® PAD System, and Predator 360°^® PAD System, are catheter-based platforms capable of treating a broad range of plaque types, including calcified plaque, in leg arteries both above and below the knee and address many of the limitations associated with existing treatment alternatives. In October 2013, the Company received premarket approval (“PMA”) from the FDA to market the Diamondback 360^® Coronary Orbital Atherectomy System (“OAS”) as a treatment for severely calcified coronary arteries. The Company began a controlled commercial launch of the Diamondback 360^®Coronary OAS following receipt of PMA approval.